The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Introduction: As a novel glucagon-like peptide-1receptor agonist (GLP-1 RA) for type 2 diabetes (T2D) treatment, the economic value of once-weekly semaglutide had been assessed in several country settings. The authors’ objective was to systematically review the existing pharmacoeconomic literature evaluating the cost-effectiveness associated with once-weekly semaglutide compared with other GLP-1 RAs and provide implications for further researches.Areas covered: We conducted a systematic literature review of cost-effectiveness analysis (CEA) published up to 25 July 2020 in PubMed, web of science, and the ISPOR presentation database, compared once-weekly semaglutide with other GLP-1 RAs in T2D. Nineteen studies were identified, including 8 short-term and 11 long-term studies. General characteristics and main results of the included studies were summarized.Expert opinion: This review provided references for other countries to overview the value of once-weekly semaglutide compared with other GLP-1 RAs in T2D in the healthcare decision-making process and to conduct their CEA studies associated with once-weekly semaglutide. The authors found that the cardiovascular (CV) benefit of once-weekly semaglutide was under-estimated in current studies and suggested that the methods of economic evaluations for novel anti-diabetic drugs with CV benefit should be improved in future researches.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While some pharmacoeconomic studies are available on GLP-1 receptor agonists, the available literature is conflicting and further studies with better economic modeling for data analysis are required.[47][48][49]”
From Tirzepatide: Clinical review of the twincretin injectable (2023) · cites this paper as [47]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“Across all the cardiovascular outcomes trials (CVOT), dulaglutide and liraglutide have also been shown with improved cardiovascular outcomes in the clinical trials of REWING [54] and LEADER [55].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“First of all, once-weekly semaglutide had been shown a significant reduction in risk of major adverse cardiovascular events in SUSTAIN 6 [25], suggested that the CV complications in diabetes may be influenced by aspects beyond the traditional risk factors such as HbA1c.”
BackgroundThe global burden of diabetic foot disease
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G., & Apelqvist, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67698-2 · Cited by 2,566
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., & Loder, E. (2013) · Value in Health · doi:10.1016/j.jval.2013.02.002 · Cited by 1,998 · cited 2×
“Data elements for extraction were chosen according to guidelines set by the ISPOR Health Economic Evaluation Publication Guidelines Task Force [36] as well as based on the authors’ experience.”
MethodIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · cited 1×
“Improved glycemic control was the main treatment target for T2D, as the benefit of lower glycated hemoglobin (HbA1c) associated with reduced risk of long-term micro- and macrovascular disease has been demonstrated in several landmark studies [10,11].”
BackgroundPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Research works printed but not linked: 4
- Capehorn MS, 2019, Diabetes Metab
- Pollock RF, 2019, Diabetic Med, 36, 170
- Tikkanen CK, 2018, Management, 12, 12
- de Wit HM, 2017, Neth J Med, 75, 272
Cited by
Valentine, W. J., Hoog, M., Mody, R., Belger, M., & Pollock, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14979 · Cited by 28
Wang, S., Wang, S., Wang, Y., & Luan, J. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01520-3 · Cited by 27
Self-citationLiu, Z., Zeng, B., Sun, F., & Xia, Q. (2025) · Diabetes Care · doi:10.2337/dc24-2241 · Cited by 17
Ruan, Z., Ung, C. O. L., Shen, Y., Zhang, Y., Wang, W., Luo, J., Zou, H., Xue, Y., Wang, Y., Hu, H., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01301-4 · Cited by 14
Self-citationMody, R., Valentine, W. J., Hoog, M. M., Sharland, H., & Belger, M. A. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.2.153 · Cited by 13
Metadata
- Authors
- Ruan, Z., Yang, L., Shi, H., Yue, X., Wang, Y., Liang, M., & Hu, H.
- Affiliations
- University of Macau (MO)
- University of Cincinnati (US)
- Imperial College London (GB)
- Corresponding author
- Hu, Hao
- Venue
- Expert Review of Pharmacoeconomics & Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2021-01-12
- Volume
- 21
- Issue
- 2
- Pages
- 221-233
- ISSN
- 1473-7167 (ISSN-L)
- 1744-8379
- OpenAlex
- W3111172371
- Cited by
- 15
- References
- 62
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 4 · 2022: 5
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Pharmacoeconomics & Outcomes Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- semaglutide, GLP-1 receptor agonists, type 2 diabetes, cost-effectiveness, cardiovascular benefits, economic evaluation, antidiabetic drugs, healthcare decision-making
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Economics, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. https://app.cochat.ai/papers/10.1080/14737167.2021.1860022
- The paper
- Ruan, Z., Yang, L., Shi, H., Yue, X., Wang, Y., Liang, M., & Hu, H. (2021). The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2021.1860022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.